Trial Profile
A randomized, double-blind, placebo controlled, parallel group, Phase II multi-centric trial to assess safety, tolerability and efficacy of PHD-2 Inhibitor, ZYAN1 in the treatment of anemia in pre-dialysis chronic kidney disease patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Jul 2019
Price :
$35
*
At a glance
- Drugs Desidustat (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors Cadila Healthcare
- 01 Jan 2019 Status changed from active, no longer recruiting to completed, according to results published in the American Journal of Nephrology.
- 11 Sep 2018 Status changed from recruiting to active, no longer recruiting.
- 09 Oct 2017 Status changed from not yet recruiting to recruiting.